Article
Insights into RAS-driven melanoma and its therapeutic implications.
Cancer treatment reviews - 1 Feb 2026
Chatziioannou Eftychia, Lallas Konstantinos, Sinnberg Tobias, Niessner Heike, Stratigos Alexander J, Flatz Lukas, Amaral Teresa
Abstract excerpt
NRAS mutations are present in 15-25 % of cutaneous melanomas, predominantly affecting codon 61 (Q61R > Q61K). Mutations at codons 12 and 13 are rare although they appear to be relatively enriched in mucosal subtype. KRAS alterations, while rare in cutaneous melanomas, are more frequently observed in melanoma brain metastases as well as in acral and mucosal subtypes, where NRAS mutations are less prevalent. For...
Topics
- Humans
- Melanoma
- Mutation
- Skin Neoplasms
- ras Proteins
- GTP Phosphohydrolases
- Molecular Targeted Therapy
- Membrane Proteins